drugset / Trial / NCT03496870
A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa.
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 1, open-label study to assess the pharmacokinetics, pharmacodynamics, safety, and tolerability of opicapone when administered orally once daily for 14 days as adjunctive therapy to carbidopa/levodopa in subjects with Parkinson's disease.
Timeline
- Start
- 2018-02-08
- Primary completion
- 2018-07-02
- Completion
- 2018-07-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Levodopa | Small molecule | — | — |
| Subject | Opicapone | Small molecule | — | Oral |
| Background | Carbidopa | Unknown | — | — |